Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2011-08-23
2011-08-23
Rooney, Nora (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
active
08003109
ABSTRACT:
Pharmaceutical compositions are described containing a long pentraxin PTX3, particularly human PTX3, for the therapy of infectious and inflammatory or tumor diseases; expression vectors containing cDNA coding for PTX3; recombinant host cells transfected with such vectors; a method for producing substantial amounts of PTX3 involving the culturing of such cells, and the use of said vectors in the gene therapy of tumors.
REFERENCES:
patent: 4751242 (1988-06-01), Calvani et al.
patent: 5426181 (1995-06-01), Lee et al.
patent: 5632983 (1997-05-01), Hadden et al.
patent: 5939423 (1999-08-01), Karlin et al.
patent: 6344320 (2002-02-01), Rothschild et al.
patent: 6872541 (2005-03-01), Mills
patent: 7041648 (2006-05-01), Mantovani
patent: 7683032 (2010-03-01), Carminati et al.
patent: 2004/0023879 (2004-02-01), Mantovani et al.
patent: 2004/0029803 (2004-02-01), Mantovani et al.
patent: 2004/0137544 (2004-07-01), Latini et al.
patent: 2004/0198655 (2004-10-01), Mantovani
patent: 2005/0152876 (2005-07-01), Mantovani
patent: 2006/0148001 (2006-07-01), Mantovani
patent: 2006/0286617 (2006-12-01), Latini et al.
patent: 2007/0098722 (2007-05-01), Bottazzi et al.
patent: 2009/0275508 (2009-11-01), Romani et al.
patent: 2009/0286726 (2009-11-01), Carminati et al.
patent: 2010/0209442 (2010-08-01), Carminati et al.
patent: WO 92/12176 (1992-07-01), None
patent: 93/21313 (1993-10-01), None
patent: 99/32516 (1999-01-01), None
patent: 2004/094991 (2004-11-01), None
patent: 2006/037744 (2006-04-01), None
Metzler et al. ‘Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28.’ Nature Structural Biol. 4:527-531, 1997.
Gewurz et al. ‘Structure and function of the pentraxins.’ Curr. Opin. Immunol. 7:54-64, 1995.
Reading et al.‘Antiviral activity of the long chain pentraxin PTX3 against influenza viruses.’ J. Immunol. 180:3391-3398, 2008.
Mairuhu et al. ‘Elevated plasma levels of the long pentraxin, pentraxin 3, in severe dengue virus infections.’ J. Med. Virol. 76:547-552, 2005.
Soares et al. ‘Dual function of the long pentraxin PTX3 in resistance against pulmonary infection withKlebsiella pneumoniaein transgenic mice.’ Microbes and Infection. 8:1321-1329, 2006.
He et al.‘Long pentraxin 3 in pulmonary infection and acute lung injury.’ Am. J. Phsiol. Lung. Cell. Mol. Physiol. 292:L1039-L1049, 2007.
Nauta, A. “Biochemical and Function Characterization of the Interaction . . . ” Eur. J. Immunol., vol. 33, pp. 465-473, 2003.
Hamazaki, H. “Structure and Significance of n-Linked Sugar Unit . . . ”, Biochemicica et Biophysica Acts., vol. 1037, pp. 435-438, 1990.
Siripont, J. et al. “Receptor-Mediated Binding of the Acute-Phase . . . ”, Cellular Immunology, vol. 117, pp. 239-252, 1988.
Tennent, G. et al. “Glycobiology of the Pentraxins”, Biochemical Society Transactions, vol. 22, No. 1, pp. 74-79, 1994.
Camozzi et al., Arterioscler Thromb Vasc Biol. Sep. 2005;25(9):1837-42. Epub Jul. 14, 2005.
Souza et al., Am J Pathol. Apr. 2009;174(4):1309-18. Epub Mar. 12, 2009.
Bassi et al., Clin Rev Allergy Immunol. Nov. 18, 2008. [Epub ahead of print], 8 pages.
Bevelacqua et al., Int J Mol Med. Sep. 2006;18(3):415-23.
Kataoka et al., Atherosclerosis. Mar. 2008;197(1 ):368-74. Epub Jul. 19, 2007.
Luchetti et al., Clin Exp Immuno12000, 119:196-202.
Rolph et al., Arterioscler Thomb Vasc Bioi 2002, 22: 1-5.
Polentarutti et al., “Interferon-Gamma Inhibits Expression of the Long Pentraxin PTX3 in Rheumatoid Arthritis (RA)” European J, Immunol., vol. 28, 1998, pp. 496-501.
Alles et al. “Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes” Blood 84:3483-3493 (1994).
Berry et al. “Mesenchymal stem cell injection after mycardial infarction improves myocardial compliance” Am. J. Physiol. Heart Circ. Physiol. 290:H2196-H2203 (2006).
Bottazzi et al. “Preliminary biochemical and biological characterization of PTX3, a new member of the pentraxin gene family” Cytokine 9:903 (1997).
Bottazzi et al. “Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component” J. Biol. Chem. 272:32817-32823 (1997).
Breviario et al. “Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component” J. Biol. Chem. 267:22190-22197 (1992).
“Carboxymethylcellulose Sodium” in The Merck Index, Eleventh Edition, p. 278 (1989).
“Chapter 3—Vitamin Deficiency, Dependency, and Toxicity” and “Chapter 202—Coronary Artery Disease” in The Merck Manual, pp. 48-49 and 1660-1661, 17th Edition, 1999.
“Choline Chloride” International Chemical Safety Card 0853, two pages (1995).
Dai et al. “A therapeutic model for advanced endometrial cancer: Systemic progestin in combination with local adenoviral-mediated progesterone receptor expression” Mol. Cancer Ther. 4:169-175 (2005).
Dictionary definition of “excipient” from internet: dict.die.net (2003).
Dictionary definition of “excipient” from Butterworths Medical Dictionary, Second Edition, p. 628 (1978).
“Dulbecco's MEM Modified Formulation” ATCC Catalog No. 30-2002 (2002).
“Folic Acid” from internet: suprahealth.com, three pages (2003).
Fordham et al. “Definition of Frequently Used Terms in Regulatory Affairs and Quality Assurance” Albany Molecular Research, Technical Reports, 3:1/11-11/11 (1999).
Gewurz et al. “Structure and function of pentraxins” Curr. Opin. Immunol. 7:54-64 (1995).
“Inositol (Vitamin B8)” in Herb Index from internet: blueprint.bluecrossmn.com, 5 pages (2003).
Introna et al. “Cloning of mouse PTX3 a new member of the pentraxin gene family expressed at extrahepatic sites.” Blood 87:1862-1872 (1996).
Mikayama et al. “Molecular cloning and functional expression of a cDNA encoding glycosylation-inhibiting factor” Proc. Natl. Acad. Sci. USA 90:10056-10060 (1993).
Moore et al. “Temporal dissociation between lithium-induced changes in frontal lobe myo-inositol and clinical response in manic-depressive illness” (abstract, two pages) Am. J. Psychiatry 156:1902-1908 (1999).
Ngo et al. in The Protein Folding Problem and Tertiary Structure Prediction, Merz et al. (eds.), Birkhauser, Boston, MA, pp. 433 and 492-495 (1994).
Skolnick et al. “From genes to protein structure and function: Novel applications of computational approaches in the genomic era” Trends in Biotechnol. 18: 34-39 (2000).
“Stability testing of new drug substances and products Q1A (R2)” in ICH Harmonised Tripartite Guideline from Int'l Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, p. 18 (2003).
Therapeutic Category and Biological Activity Index from internet: www.merckbooks.com, The Merck Index, pp. THER-1 and THER-26 (2002).
Vouret-Craviari et al. “Expression of a long pentraxin, PTX3, by monocytes exposed to the mycobacterial cell wall component lipoarabinomannan” Infect. Immun. 65:1345-1350 (1997).
Bottazzi Barbara
Introna Martino
Mantovani Alberto
Vecchi Annunciata
Lucas & Mercanti LLP
Rooney Nora
Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
LandOfFree
Pharmaceutical compositions containing the long pentraxin PTX3 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions containing the long pentraxin PTX3, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions containing the long pentraxin PTX3 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2726682